# Diversity supplement for Oliver Viyar to receive research training in tissue engineering.

> **NIH NIH R44** · TEMPO THERAPEUTICS, INC. · 2020 · $24,685

## Abstract

SUMMARY / ABSTRACT
This supplement is submitted under the parent grant “MAP: a flowable, precision-engineered, and tunable
tissue scaffold leveraging hyper-porous geometry to control inflammation and promote regenerative healing in
diabetic wounds” and is for Oliver Viyar B.S., who will be the diversity investigator as a Filipino American
minority on the application. Mr. Viyar is a post-baccalaureate researcher, who has demonstrated an interest in
and wish to pursue research training in health-related sciences while applying for admission to graduate school.
Mr. Voyar wishes to enroll in a PhD program for biomedical engineering with the ultimate goal to pursue his
career as a lead scientist in the biotechnology industry. He seeks additional research training prior to applying
for admission to PhD programs. Mr. Viyar received his Bachelor of Science degree in May 2019 in Chemical
Engineering at the University of Virginia. After his graduation, Mr. Viyar began working as a research assistant
at Tempo Therapeutics, Inc.
The overall goal of the parent grant is to continue the development of the Microporous Annealed Particle
(MAP) biomaterial technology for the treatment of impaired diabetic foot ulcers (DFUs). Our MAP materials are
flowable (ease of application) and fill wounds of multiple shapes and sizes and convert to a hyper-porous
sponge-like network in the wound site after exposure to LED white light. The hyper-porosity geometry
promotes fast tissue ingrowth, early vascularization, and faster wound re-epithelialization when compared to
leading decellularized tissue-based matrices, with minimal inflammatory response. We are employing
specialized models of impaired wound healing in diabetic pigs to test a suite of three formulation variants
already demonstrated in a preliminary healthy swine study. The optimal formulation of MAP that performs in
slow healing environments and stimulates tissue regeneration will be selected for safety profiling and an
Investigational Device Exemption (IDE) will be submitted at the end of the proposal.
In this supplement and in regard to this parent grant, Mr. Viyar will be working directly under Dr. Deshayes’
supervision with the main goal to optimize one step of the manufacturing process for the fabrication of the
hydrogel microspheres that compose the MAP product. The current manufacturing process faces some
challenges of scalability and sterility. Therefore, Mr. Viyar will investigate the use of a static mixing method
rather than a mechanical stirring method to fabricate the hydrogel microspheres in order to enhance the
production scale and ease the aseptic process. Dr. Deshayes will provide him with both research mentorship
and career guidance. In addition, Mr. Viyar will receive exposure to pre-clinical studies on large animals and
regulatory process.

## Key facts

- **NIH application ID:** 10075090
- **Project number:** 3R44DK124085-01S1
- **Recipient organization:** TEMPO THERAPEUTICS, INC.
- **Principal Investigator:** Stephanie Deshayes
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $24,685
- **Award type:** 3
- **Project period:** 2019-09-15 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10075090

## Citation

> US National Institutes of Health, RePORTER application 10075090, Diversity supplement for Oliver Viyar to receive research training in tissue engineering. (3R44DK124085-01S1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10075090. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*